| Sector |
Miscellaneous
|
Compare with Sector peers |
| Industry |
Miscellaneous
|
Compare with Industry peers |
| Website | http://www.vantabio.com | |
| Market Cap | 30.11 Cr. | |
| Enterprise Value(EV) | 47.33 Cr. | 2021-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.14 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | 342.21 | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 42.81 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 37.89 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 1.26 | Calculated using Price: 47.71 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 0.63 Cr. | 6,312,000 Shares |
| FaceValue | 10 | |
| About Vanta Bioscience Ltd. | ||
| The company is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition they also provide risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. VBS also provides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers. Their services include toxicology, batch release tests, biocompatibility studies, chemical safety, and diet formulation. | ||
| 1 Day |
|
-5.00% |
| 1 Week |
|
-6.45% |
| 1 Month |
|
-8.69% |
| 3 Month |
|
-37.63% |
| 6 Month |
|
-38.40% |
| 1 Year |
|
-51.32% |
| 2 Year |
|
-72.74% |
| 5 Year |
|
-1.63% |
| 10 Year |
|
| 3 years | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 3.14 | 4.43 | 1.89 | |
| Return on Capital Employed (%) | 7.87 | 8.62 | 5.42 | |
| Return on Assets (%) | 1.78 | 2.31 | 0.76 |
| Particulars | 3 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Shh. Funds | 22 | 23 | 24 | |
| Non Curr. Liab. | 13 | 14 | 29 | |
| Curr. Liab. | 3 | 10 | 15 | |
| Minority Int. | 1 | 1 | 2 | |
| Equity & Liab. | 39 | 49 | 70 | |
| Non Curr. Assets | 22 | 29 | 50 | |
| Curr. Assets | 17 | 20 | 20 | |
| Misc. Exp. not W/O | ||||
| Total Assets | 39 | 49 | 70 |
| Particulars | 3 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Net Sales | 12 | 14 | 10 | |
| Other Income | 0 | 0 | 0 | |
| Total Income | 12 | 14 | 10 | |
| Total Expenditure | -9 | -9 | -6 | |
| PBIDT | 4 | 4 | 4 | |
| Interest | -2 | -2 | -2 | |
| Depreciation | -1 | -1 | -1 | |
| Taxation | 0 | 0 | 0 | |
| Exceptional Items | ||||
| PAT | 1 | 1 | 0 | |
| Minority Interest | 0 | |||
| Share Associate | ||||
| Other Related Items | ||||
| Consolidated Net Profit | 1 | 1 | 0 | |
| Adjusted EPS | 1 | 2 | 1 |
| Particulars | 3 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | -1 | 2 | 7 | |
| Cash Fr. Inv. | -6 | -7 | -22 | |
| Cash Fr. Finan. | 10 | 2 | 18 | |
| Net Change | 3 | -3 | 2 | |
| Cash & Cash Eqvt | 3 | 0 | 3 |
|
Tue, 30 May 2023
Announcement under Regulation 30 (LODR)-Meeting Updates Intimation regarding postponement of Board Meeting dated 30.05.2023 for approval of financial results of the Company |
|
Mon, 22 May 2023
Board Meeting Intimation for Approval Of Financial Statements For The Period Ended 30.09.2022 And 31.03.2023 Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve financial statements for the period ended 30.09.2022 and 31.03.2023 |
|
Sun, 30 Apr 2023
Compliance Certificate Under Regulation 40(9) Of SEBI (LODR) Regulations 2015 For The Year Ended March 31 2023 Compliance Certificate under Regulation 40(9) of SEBI (LODR) Regulations 2015 for the year ended March 31 2023 |
| Thu, 01 Jun 2023 |
Close Crossing Last Week Low
|
Close Crossing Last Month Low
|
Close Crossing Last Month Close from Above
|
Close Crossing 52 Week Low
|
Opening at High
|
Equities
M.F.
Sectors
StockEdge Social